Eze K. Abosi currently serves as a Vice President of New Product for Optum. In this role, he supports the commercialization of Clinical Trial Optimization, Clinicogenomics, and NLP based solutions from Optum Life Sciences. In addition, Eze leads innovative partnerships on behalf of the Optum Growth Office. Eze has accumulated 16 years of experience supporting the life sciences with data, analytics, and consulting services, in various roles of increasing responsibility throughout his career. He earned a Bachelor’s of Science from Union College (NY) and obtained his Masters in General Management from Harvard University.
Track Chair: - Courtney McFall, UCSF
- Ben Rubin, UCSF
Patient-centric data – Real-World Evidence (RWE) and Real-World Data (RWD) - is becoming instrumental in the drug development process and for health care decisions in general. This data is not only informative for the process from discovery to new indications, clinical trial design, and drug development, it also can be of value to monitor post-marketing drug safety and for decision support in clinical practice. As the data becomes a decision driver, science companies and medical organizations are increasingly focused on leveraging RWD and RWE to not only better understand the patient populations using their drugs and the respective outcomes, but also to accelerate clinical decision support. This session will focus on the various aspects of integrating RWE and RWD to support drug development and clinical decision support.